| RS2110133917 |
PKD2
|
Health Risk |
Conflicting classifications of pathogenicity |
Polycystic kidney disease 2, Polycystic kidney disease 2 |
| RS2110133920 |
PKD2
|
Health Risk |
Pathogenic/Likely pathogenic |
Hyperechogenic kidneys, Multiple renal cysts |
| RS2110133998 |
PKD2
|
Health Risk |
Pathogenic |
Polycystic kidney disease 2, Polycystic kidney disease 2 |
| RS2110134005 |
PKD2
|
Health Risk |
Pathogenic |
Autosomal dominant polycystic kidney disease, Polycystic kidney disease 2 |
| RS2110137964 |
PKD2
|
Health Risk |
Pathogenic |
Autosomal dominant polycystic kidney disease, Autosomal dominant polycystic kidney disease |
| RS2110138755 |
PKD2
|
Health Risk |
Pathogenic/Likely pathogenic |
Polycystic kidney disease 2, Polycystic kidney disease 2 |
| RS2110139489 |
CNGA1
|
Health Risk |
Pathogenic |
— |
| RS2110141387 |
PKD2
|
Health Risk |
Pathogenic |
Polycystic kidney disease 2, Polycystic kidney disease 2 |
| RS2110141740 |
CNGA1
|
Health Risk |
Likely pathogenic |
— |
| RS2110150747 |
PKD2
|
Health Risk |
Pathogenic |
Autosomal dominant polycystic kidney disease, Autosomal dominant polycystic kidney disease |
| RS2110155552 |
FRAS1
|
Health Risk |
Pathogenic |
Renal agenesis, Renal agenesis |
| RS2110157889 |
CNGA1
|
Health Risk |
Pathogenic |
— |
| RS2110165980 |
ANKRD17
|
Health Risk |
Likely pathogenic |
Chopra-Amiel-Gordon syndrome, Chopra-Amiel-Gordon syndrome |
| RS2110167415 |
ANKRD17
|
Health Risk |
Pathogenic |
Chopra-Amiel-Gordon syndrome, Chopra-Amiel-Gordon syndrome |
| RS2110190526 |
PPP3CA
|
Health Risk |
Likely pathogenic |
— |
| RS2110193521 |
HTT
|
Health Risk |
Pathogenic |
— |
| RS2110205188 |
PPP3CA
|
Health Risk |
Pathogenic |
Developmental and epileptic encephalopathy 91, Developmental and epileptic encephalopathy 91 |
| RS2110205238 |
PPP3CA
|
Health Risk |
Pathogenic |
— |
| RS2110210889 |
PPP3CA
|
Health Risk |
Likely pathogenic |
— |
| RS2110211759 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110212658 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110212747 |
MTTP
|
Health Risk |
Pathogenic |
Abetalipoproteinaemia, Abetalipoproteinaemia |
| RS2110217058 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110217173 |
MTTP
|
Health Risk |
Pathogenic |
Abetalipoproteinaemia, Abetalipoproteinaemia |
| RS2110217457 |
RAP1GDS1
|
Health Risk |
Pathogenic |
Alfadhel syndrome, Alfadhel syndrome |
| RS2110218614 |
MTTP
|
Health Risk |
Pathogenic |
Abetalipoproteinaemia, Abetalipoproteinaemia |
| RS2110222141 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110222234 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110222265 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110225080 |
PPP3CA
|
Health Risk |
Conflicting classifications of pathogenicity |
Developmental and epileptic encephalopathy 91, Arthrogryposis |
| RS2110225482 |
MTTP
|
Health Risk |
Likely pathogenic |
— |
| RS2110228616 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110230118 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110230146 |
MTTP
|
Health Risk |
Pathogenic/Likely pathogenic |
Abetalipoproteinaemia, Metabolic syndrome X |
| RS2110230220 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110230260 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110231198 |
TET2
|
Health Risk |
Pathogenic |
Myelodysplastic syndrome, Myelodysplastic syndrome |
| RS2110231743 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110232389 |
TET2
|
Health Risk |
Pathogenic |
EBV-positive nodal T- and NK-cell lymphoma, EBV-positive nodal T- and NK-cell lymphoma |
| RS2110233238 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110234873 |
TET2
|
Health Risk |
Pathogenic |
— |
| RS2110237031 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110237126 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110237946 |
TET2
|
Health Risk |
Pathogenic |
— |
| RS2110238237 |
MTTP
|
Health Risk |
Likely pathogenic |
— |
| RS2110238242 |
MTTP
|
Health Risk |
Pathogenic |
— |
| RS2110243783 |
PDGFRA
|
Health Risk |
Conflicting classifications of pathogenicity |
Gastrointestinal stromal tumor, Hereditary cancer-predisposing syndrome |
| RS2110249286 |
TET2
|
Health Risk |
Pathogenic |
— |
| RS2110249810 |
PPP3CA
|
Health Risk |
Likely pathogenic |
— |
| RS2110249848 |
PPP3CA
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2110253722 |
PPP3CA
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy 91, Arthrogryposis |
| RS2110266368 |
PDGFRA
|
Health Risk |
Conflicting classifications of pathogenicity |
Gastrointestinal stromal tumor, Hereditary cancer-predisposing syndrome |
| RS2110266515 |
PDGFRA
|
Health Risk |
Conflicting classifications of pathogenicity |
Gastrointestinal stromal tumor, Hereditary cancer-predisposing syndrome |
| RS2110266987 |
LEF1
|
Health Risk |
Pathogenic |
Ectrodactyly, Ectodermal dysplasia 17 with or without limb malformations |
| RS2110269472 |
HTT
|
Health Risk |
Pathogenic |
— |
| RS2110293461 |
PDGFRA
|
Health Risk |
Conflicting classifications of pathogenicity |
Gastrointestinal stromal tumor, Hereditary cancer-predisposing syndrome |
| RS2110296349 |
HTT
|
Health Risk |
Likely pathogenic |
— |
| RS2110296712 |
FRAS1
|
Health Risk |
Pathogenic |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2110306146 |
TET2
|
Health Risk |
Pathogenic |
— |
| RS2110315013 |
TET2
|
Health Risk |
Pathogenic |
EBV-positive nodal T- and NK-cell lymphoma, EBV-positive nodal T- and NK-cell lymphoma |
| RS2110319166 |
FRAS1
|
Health Risk |
Pathogenic |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2110325478 |
FRAS1
|
Health Risk |
Likely pathogenic |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2110330572 |
FRAS1
|
Health Risk |
Pathogenic |
— |
| RS2110338263 |
PDGFRA
|
Health Risk |
Pathogenic |
Polyps, multiple and recurrent inflammatory fibroid |
| RS2110348535 |
PPP3CA
|
Health Risk |
Likely pathogenic |
Developmental and epileptic encephalopathy 91, Developmental and epileptic encephalopathy 91 |
| RS2110353283 |
FRAS1
|
Health Risk |
Conflicting classifications of pathogenicity |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2110390266 |
FRAS1
|
Health Risk |
Pathogenic |
Fraser syndrome 1, Fraser syndrome 1 |
| RS2110420831 |
SEC24D
|
Health Risk |
Pathogenic |
— |
| RS2110431524 |
PITX2
|
Health Risk |
Pathogenic |
Axenfeld-Rieger syndrome type 1, Anterior segment dysgenesis 4 |
| RS2110432091 |
PITX2
|
Health Risk |
Pathogenic |
Axenfeld-Rieger syndrome type 1, Anterior segment dysgenesis 4 |
| RS2110433384 |
LEF1
|
Health Risk |
Pathogenic |
Ectrodactyly and ectodermal dysplasia without cleft lip/palate, Ectrodactyly and ectodermal dysplasia without cleft lip/palate |
| RS2110435639 |
PITX2
|
Health Risk |
Likely pathogenic |
Axenfeld-Rieger syndrome type 1, Axenfeld-Rieger syndrome type 1 |
| RS2110435645 |
PITX2
|
Health Risk |
Pathogenic |
Anterior segment dysgenesis 4, Axenfeld-Rieger syndrome type 1 |
| RS2110435742 |
PITX2
|
Health Risk |
Pathogenic/Likely pathogenic |
Axenfeld-Rieger syndrome type 1, Anterior segment dysgenesis 4 |
| RS2110435882 |
PITX2
|
Health Risk |
Likely pathogenic |
Axenfeld-Rieger syndrome type 1, Axenfeld-Rieger syndrome type 1 |
| RS2110525413 |
SNCA
|
Health Risk |
Conflicting classifications of pathogenicity |
Autosomal dominant Parkinson disease 1, Autosomal dominant Parkinson disease 4 |
| RS2110800853 |
NAA15
|
Health Risk |
Likely pathogenic |
— |
| RS2110806028 |
FGA
|
Health Risk |
Pathogenic |
Congenital afibrinogenemia, Congenital afibrinogenemia |
| RS2110808262 |
FGA
|
Health Risk |
Likely pathogenic |
— |
| RS2110812642 |
FGA
|
Health Risk |
Pathogenic |
— |
| RS2110819800 |
FGA
|
Health Risk |
Likely pathogenic |
— |
| RS2110841438 |
FGG
|
Health Risk |
Conflicting classifications of pathogenicity |
— |
| RS2110850824 |
FGG
|
Health Risk |
Pathogenic |
Familial dysfibrinogenemia, Familial dysfibrinogenemia |
| RS2110894530 |
NAF1
|
Health Risk |
Likely pathogenic |
— |
| RS2110895965 |
NAA15
|
Health Risk |
Conflicting classifications of pathogenicity |
Intellectual disability, autosomal dominant 50 |
| RS2110902008 |
NAA15
|
Health Risk |
Likely pathogenic |
Neurodevelopmental disorder, Neurodevelopmental disorder |
| RS2110911005 |
NAA15
|
Health Risk |
Pathogenic |
— |
| RS2110911054 |
NAA15
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110915238 |
NAA15
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110915306 |
NAA15
|
Health Risk |
Pathogenic |
— |
| RS2110930000 |
NAA15
|
Health Risk |
Pathogenic |
— |
| RS2110930005 |
NAA15
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110930242 |
NAA15
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110934149 |
NAA15
|
Health Risk |
Conflicting classifications of pathogenicity |
Intellectual disability, autosomal dominant 50 |
| RS2110935003 |
NAA15
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110935239 |
NAA15
|
Health Risk |
Pathogenic |
Autism, Autism |
| RS2110941169 |
NAA15
|
Health Risk |
Pathogenic |
Neurodevelopmental delay, Neurodevelopmental delay |
| RS2110941246 |
NAA15
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110948948 |
NAA15
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 50 |
| RS2110949021 |
NAA15
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 50 |